This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.
No takes yet. Share an insight, caveat, or question.
Kazi et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: